Illumina Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 364 M240 M234 M284 M321 M 1.08 B Mittelzufluss aus Investitionstätigkeit -48 M-63 M-49 M-51 M108 M -55 M Zahlungsströme aus der Finanzierungstätigkeit -47 M-195 M-371 M-115 M-63 M -744 M Freier Cashflow 335 M208 M204 M253 M266 M 931 M

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.

ILMN

Financials

Illumina Inc

Nachrichten

Three Best Genomics Stocks for Your Portfolio in 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Illumina Stock: Competitive Threats Priced In (NASDAQ:ILMN)

REGN or ILMN: Which Is the Better Value Stock Right Now?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Argus hebt Illumina-Kursziel wegen neuer Produkte auf 145 US-Dollar an

Canaccord bestätigt "Halten"-Rating für Illumina-Aktie angesichts Roche-Konkurrenz

ILMN Stock Gains Following Expanded Collaboration With Labcorp

Illumina und Labcorp vertiefen Partnerschaft in der Krebsdiagnostik

Illumina und Veritas bringen Genomsequenzierung in die Krankenversicherung/n

Illumina partners with Veritas to offer genome sequencing via insurers